Adjuvance
PRIVATE
STATUS
Seed
LATEST DEAL TYPE
$2.72M
LATEST DEAL AMOUNT
2
INVESTORS
Description
Operator of a bio-pharmaceutical company designed to offer vaccines. The company's SAPONEX products are critical components that are added to many vaccines, enabling people to improve their immunity system.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Pharmaceuticals
Primary Office
- 116 West 22nd Street
- 6th Floor
- New York, NY 10010
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Adjuvance’s full profile, request a free trial.
Adjuvance Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Seed Round | 14-Oct-2015 | $2.72M | 00.000 | Completed | Generating Revenue | |
| 1. Grant | 31-May-2015 | 00.00 | Completed | Generating Revenue |
Adjuvance Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Invest Nebraska | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 |
Adjuvance Executive Team (6)
2 Former Executives
You’re viewing 4 of 6 executives. Get the full list »Adjuvance Board Members (6)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Gregory Poland | Adjuvance | Vice Chairman & Advisor | 000 0000 | |
| John Gallo | Adjuvance | Board Member | 000 0000 | |
| Mary Gin | Adjuvance | Board Member | 000 0000 | |
| Tyler Martin | Adjuvance | Chairman & Chief Executive Officer | 000 0000 |
2 Former Board Members
You’re viewing 4 of 6 board members. Get the full list »